What the FDA Said and Why Now
The FDA has told clinicians it is investigating something unusual: previously healthy patients suffering severe brain injury or death after routine general anesthesia, with a specific inherited genetic change turning up in many of them.
In an alert published July 2, the agency said it is examining the safety of sevoflurane and other general anesthetics after published reports of catastrophic outcomes, including severe neurologic harm and death, in adult and pediatric patients of maternal Venezuelan ancestry following routine anesthesia with sevoflurane.
The reason for the timing is humanitarian rather than clinical. The FDA said that in light of recent earthquakes in Venezuela, it wanted agencies sending medical resources there, and clinicians traveling to work there, to know about these events before meeting them in an operating room.
The interim suggestion is directed at that setting specifically. Groups providing medical care in Venezuela may consider alternatives to volatile anesthetics, such as intravenous or regional anesthesia, where clinically appropriate and available.
For patients in the United States, the agency was careful about what it did not say. It stated it is "continuing to review this emerging safety concern" for what it may mean for the US population and approved anesthetic products. No change to US labeling or practice has been announced.
How a Mitochondrial Variant Changes Anesthetic Response
The biology here is unusually clean for an emerging safety question, which is part of why researchers took it seriously.
Mitochondria are the structures inside cells that produce energy, and they do it through a chain of protein complexes. The first of these, called complex I, is where the genetic change in question sits. The variant, designated MT-ND4 m.11232T>C, affects a subunit of complex I.
Volatile anesthetics, sevoflurane among them, are known to inhibit complex I. In most people that has no meaningful consequence. Published experimental work indicates that at concentrations reached during ordinary surgery, sevoflurane can suppress complex I enough to substantially reduce cellular oxygen consumption and energy production.
The pattern reported in affected patients is that they appear entirely healthy beforehand, with no signs of mitochondrial disease, until anesthetic exposure. The anesthetic acts as the trigger on an already narrowed margin, and the brain, which tolerates energy failure poorly, is where the damage shows.
The FDA drew the obvious inference. While reported cases have involved sevoflurane, the agency wrote, "this genetic variant raises concerns regarding all volatile anesthetics."
Propofol, an intravenous anesthetic, also interacts with complex I, and professional guidance notes that the relative risk between it and sevoflurane in these patients is not established.
Why This Tracks Maternal Lineage, Not Nationality
This distinction is the one most likely to be reported carelessly, and getting it right matters both for accuracy and for the people involved.
Mitochondrial DNA is inherited only from the mother. A person receives it from their mother, who received it from hers, in an unbroken maternal line. Nuclear DNA, which carries most of what people think of as inherited traits, comes from both parents. This variant sits in mitochondrial DNA, so it follows maternal lineage exclusively.
That is why clinical descriptions specify maternal Venezuelan ancestry rather than nationality or ethnicity. Someone whose father is Venezuelan and whose mother is not does not inherit it through him. Someone whose maternal grandmother came from the affected lineage may carry it while having little connection to Venezuela themselves.
It is also why the risk is not a statement about a country. The variant appears to have arisen in a specific maternal lineage. Most people of Venezuelan descent do not carry it, and the vast majority of people who receive sevoflurane anywhere in the world experience no problem.
The pattern within families is not tidy either. Reports describe affected patients who had relatives with anesthesia-related complications alongside other relatives who had entirely uneventful anesthetics.
How Rare This Is, and What Remains Unknown
Proportion belongs here, and so does honesty about the limits of the evidence.
Reporting in the anesthesiology literature described at least 36 cases since 2021 across the United States, Spain and several Latin American countries, with a concentration among boys. Genetic testing in one early series found the variant in 10 of 14 tested cases. Against the tens of millions of anesthetics given worldwide each year, this is very rare.
The concern predates the FDA alert. South American anesthesiology societies raised it first. The American Society of Anesthesiologists, the Society for Pediatric Anesthesia and Wake Up Safe issued a joint warning in July 2025 and updated it that January with heightened concern. Chile's health ministry produced a report, and European and international anesthesia bodies have followed.
Several things remain genuinely unresolved. The variant is classified as of uncertain clinical significance under standard genetic interpretation guidelines, and some laboratories historically treated it as a harmless polymorphism, which complicates interpreting a past test result. Additional mitochondrial variants have been found in affected patients, suggesting more than one genetic contributor. And the safest anesthetic for a carrier has not been established.
The professional guidance says so directly, noting that its recommendations are offered in a situation where "much more is unknown than known."
What Patients and Families Should Do
The useful action is a conversation, not a decision about whether to have surgery.
Anyone whose maternal line traces to Venezuela should mention it during pre-anesthesia assessment, even if it feels remote. So should anyone with a family history of an unexplained bad outcome after anesthesia, particularly on the mother's side. That includes a relative who had a stroke, seizure, prolonged failure to wake, or unexplained neurologic injury after a routine procedure.
Say it explicitly to the anesthesiologist rather than assuming it is in the chart. Anesthesia teams have received guidance on this and know what to do with the information, which may include choosing a different technique or arranging genetics input.
Interim guidance for known or suspected carriers has leaned toward avoiding volatile anesthetics, considering regional anesthesia where the procedure allows, and monitoring anesthetic depth. Midazolam, dexmedetomidine, ketamine, and short-acting opioids have not been implicated. Those are decisions for the anesthesia team, not the patient.
Nobody should cancel or delay needed surgery over this. General anesthesia remains very safe for the overwhelming majority of patients, and untreated surgical disease carries its own risks. Nor should anyone seek genetic testing on their own initiative without guidance, since the variant's uncertain classification means a result is difficult to interpret without a clinical geneticist or mitochondrial disease specialist.
Adverse events can be reported to the FDA's MedWatch program at 1-800-332-1088.
The confirmed fact is that the FDA is investigating catastrophic neurologic outcomes after sevoflurane in patients carrying a mitochondrial variant inherited through maternal lineage. Those most affected are people whose maternal ancestry traces to the implicated lineage, particularly children. The reasonable action is disclosing maternal ancestry and family anesthesia history before surgery. The central uncertainties are how many carriers exist and which anesthetic is safest for them. The next expected development is the FDA's assessment of implications for the US population.
Frequently Asked Questions
What is the FDA investigating? Severe neurologic outcomes and deaths following routine general anesthesia with sevoflurane in patients carrying a rare mitochondrial variant, MT-ND4 m.11232T>C.
Why does maternal ancestry matter? Mitochondrial DNA is inherited only from the mother. The variant follows an unbroken maternal line, so a Venezuelan father would not pass it on.
Does this mean people of Venezuelan descent should avoid anesthesia? No. Most people of Venezuelan descent do not carry the variant, and general anesthesia remains very safe for the overwhelming majority of patients.
How many cases are there? Reporting described at least 36 cases since 2021 across the United States, Spain, and several Latin American countries, against tens of millions of anesthetics given annually.
What should I tell my anesthesiologist? Mention if your maternal line traces to Venezuela, and any family history on your mother's side of unexplained neurologic injury after anesthesia.
Should I get genetic testing? Not on your own initiative. The variant is classified as of uncertain significance, and results need interpretation by a clinical geneticist or mitochondrial specialist.
Has US practice changed? No. The FDA says it is still reviewing implications for the US population and approved anesthetic products. Its interim suggestion was directed at care provided in Venezuela.
